A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Phase: PHASE2 | Sponsor: Queen's University | Compound: Psilocybin
- Status
- recruiting
- Institution
- Queen's University
- Start date
- 2025-05-06
- End date
- 2026-08-30
- Registry ID
- NCT06969170
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.